Abstract:Abstract Background Currently, few studies focus on the association between gut microbiota and systemic lupus erythematosus (SLE), and much less studies consider the effect of drug usage. Proton pump inhibitors (PPIs) are commonly used to treat drug-related gastrointestinal damage in SLE patients. Therefore, the purpose of this study is to examine the gut microbiota of SLE patients using PPIs. Methods Fecal samples from 20 SLE patients with PPIs (P-SLE), 20 SLE patients without PPIs (NP-SLE) and 17 healthy controls (HCs) were obtained. The structure of the bacterial community in the fecal samples was analyzed by 16S rRNA gene sequencing. Redundancy analysis (RDA) was performed to observe the relationship between clinical variables and microbiome composition in P-SLE and NP-SLE patients. Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, functional capabilities of microbiota were estimated. Network analysis was performed to analyze the association of metabolic pathway alterations with altered gut microbiota in P-SLE and NP-SLE patients. Results P-SLE patients exhibited increased alpha-diversity and an altered composition of the gut microbiota compared with NP-SLE patients. The alpha-diversity of NP-SLE patients was significantly lower than HCs but also of P-SLE patients, whose alpha-diversity had become similar to HCs. Compared with NP-SLE patients, the relative abundances of Lactobacillus , Roseburia , Oxalobacter , and Desulfovibrio were increased, while those of Veillonella , Escherichia , Morganella , Pseudomonas and Stenotrophomonas were decreased in P-SLE patients. RDA indicated that PPI use was the only significant exploratory variable for the microbiome composition when comparing SLE patients. KEGG analysis showed that 16 metabolic pathways were significantly different between NP-SLE and P-SLE patients. These metabolic pathways were mainly associated with changes in Escherichia , Roseburia , Stenotrophomonas , Morganella and Alipipes as determined by the network analysis. Conclusions PPI use is associated with an improved microbiome composition of SLE patients as it 1) increases alpha-diversity levels back to normal, 2) increases the abundance of various (beneficial) commensals, and 3) decreases the abundance of certain opportunistic pathogenic genera such as Escherichia . Validation studies with higher patient numbers are however recommended to explore these patterns in more detail.

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Proton Pump Inhibitors and Oral–Gut Microbiota: From Mechanism to Clinical Significance

Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics

Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study

Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota

Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease

Effects of proton pump inhibitors on inflammatory bowel disease: An updated review

Current situation of progress in long-term use of proton pump inhibitors may increase the risk of dementia

Compared to Histamine-2 Receptor Antagonist, Proton Pump Inhibitor Induces Stronger Oral-to-gut Microbial Transmission and Gut Microbiome Alterations: a Randomised Controlled Trial.

Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors

Alterations in gut microbiota and bile acids by proton-pump inhibitor use and possible mediating effects on elevated glucose levels and insulin resistance

Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients

Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice

Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial

Proton-pump inhibitors increase infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model

Influence of gastric acid suppression on the structure and diversity of the jejunal microbiota in a rat model

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats

Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection

Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia